Claims for Patent: 9,675,696

Summary for Patent: 9,675,696

Title:	Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain
Abstract:	A method and kits thereof for increasing the efficiency of anti-adhesive compositions by parenterally administering a composition comprising an effective amount of at least one pharmaceutically-acceptable anti-adhesive non-ionic polymer to a site of injury, controlling inflammation at the site of injury, and reducing pain.
Inventor(s):	Chamness; Kathy L. (Memphis, TN)
Assignee:	Warsaw Orthopedic, Inc. (Warsaw, IN)
Application Number:	11/598,397
Patent Claims:	1. A method of increasing the efficacy of anti-adhesive compositions, the method comprising: after creation of a neuronal injury and prior to inflammation at the site of the injury parenterally administering an injectable liquid composition comprising an effective amount of a pharmaceutically-acceptable anti-adhesive non-ionic polymer mixture, and a magnesium salt to the site of injury; controlling inflammation at the site of injury; and reducing pain, wherein the pharmaceutically-acceptable anti-adhesive non-ionic polymer mixture consists of PEG (polyethylene glycol) at a concentration of 30% volume per volume of the composition and sodium hyaluronate, and the magnesium salt consists of magnesium chloride which forms a complex with the oxygen groups of PEG; wherein the injectable liquid composition is not a gel. 2. The method according to claim 1 wherein the anti-adhesive non-ionic polymer is administered between one minute and one hour after creation of the injury. 3. The method according to claim 1 wherein a surgery is a creation of the injury. 4. The method according to claim 3 wherein the surgery is selected from the group consisting of orthopedic surgery, neurosurgery, and insertion of a medical device. 5. The method according to claim 1 wherein the composition further comprises an effective amount of at least one agent selected from the group consisting of analgesic agents, anti-inflammatory agents and immunosuppressants. 6. The method according to claim 5 wherein at least one analgesic agent is selected from the group consisting of an NSAID and a salicylate. 7. The method according to claim 5 wherein at least one anti-inflammatory agent is selected from the group consisting of a corticosteroid and an anti-inflammatory biopharmaceutical. 8. The method according to claim 5 wherein at least one immunosuppressant is selected from the group consisting of Abetimus Sodium, Antilymphocyte Immunoglobulins, Azathioprine, Basiliximab, Brequinar Sodium, Cyclosporin, Daclizumab, Everolimus, Gavilimomab, Gusperimus Hydrochloride, Inolimomab, Mizoribine, Muromonab-CD3, Mycophenolate, Repertaxin 1-lysine, Sirolimus, or Tacrolimus. 9. A method of increasing the efficacy of anti-adhesive compositions, the method comprising: parenterally administering an injectable liquid composition comprising an effective amount of a pharmaceutically-acceptable anti-adhesive non-ionic polymer mixture and a magnesium salt or the site of a neuronal injury; controlling inflammation at the site of injury; and reducing pain, wherein the anti-adhesive non-ionic polymer mixture consists of PEG (polyethylene glycol) at a concentration of 30% volume per volume of the composition and sodium hyaluronate and the magnesium salt consists of magnesium chloride which forms a complex with the oxygen groups of PEG; wherein the injectable liquid composition is not a gel. 10. The method of claim 9, wherein the neuronal injury comprises a spinal cord injury. 11. The method of claim 9, wherein the neuronal injury comprises a brain injury. 12. The method of claim 9, wherein the neuronal injury comprises an ischemic and hemorrhagic stroke, spinal cord, brain, cranial nerve or peripheral nerve injuries. 13. The method of claim 9, wherein the neuronal injury comprises an ischemic stroke. 14. The method of claim 9, wherein the neuronal injury comprises a hemorrhagic stroke. 15. The method of claim 9, wherein the neuronal injury comprises a cranial nerve injury. 16. The method of claim 9, wherein the neuronal injury comprises a peripheral nerve injury.

Details for Patent 9,675,696

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Centocor Ortho Biotech Products, L.p.	ORTHOCLONE OKT3	muromanab-cd3	Injection	103463	09/14/1992		2039-02-26
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2039-02-26
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	05/12/1998		2039-02-26
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	01/02/2003		2039-02-26
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029	05/27/2016		2039-02-26
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029	05/26/2017		2039-02-26